SeniorJournal.com - Daily News for Senior Citizens

  FRONT PAGE • Aging • Health • Alzheimer's - Mental • Nutrition • Medicare & Medicaid • Politics  • Fitness  • Social Security • Alerts • Sex Health • Features • Retirement • Elder Care  >Search  >Senior Links

[NavBar.htm]

Senior Journal: Today's News and Information for Senior Citizens & Baby Boomers

More Senior Citizen News and Information Than Any Other Source - SeniorJournal.com

• Go to more on Health & Medicine or More Senior News from SeniorJournal.com on the Front Page

   
Follow on  and 

E-mail this page to a friend!

Health & Medicine for Senior Citizens

Why Observing Prostate Cancer Gaining Ground On Surgery: NIH Panel Says Not Cancer

‘Some think these tumors should be rebranded as something else, such as idle tumors’

By Richard Knox, NPR’s Shots blog

Dec. 9, 2011 - A federally convened panel of experts says most men with newly diagnosed prostate cancer should be offered the chance to put off treatment in favor of medical monitoring of their condition. In fact, the panel went so far as to say doctors should stop calling most of these low-risk tumors cancer at all.

"Strong consideration should be given to removing the anxiety-provoking term 'cancer' for this condition," the 13-member panel says in its draft recommendations, which were produced after two days of presentation and debate.

 

Related Archive Stories

 
 

Delay of Treatment for Low-Risk Prostate Cancer Gets Nod from NIH Panel

Recommends active monitoring but details of strategies not determined

Dec. 8, 2011

Cardiovascular Deaths Not Linked with ADT for Prostate Cancer but Lower All- Death Risk May Be

Study should be 'generally reassuring' to most men with unfavorable-risk prostate cancer considering ADT, because it was associated with improved survival  - Dec. 7, 2011

Prostate Cancer Patients Considering Suicide May Find Help in New Concept

Patients who have these negative thoughts before surgery are more likely to have a lower perceived quality of life 3 months afterwards

Oct. 31, 2011

Influential Panel Giving Thumbs Down To Routine PSA Test for Prostate Cancer

See links to other comments and reports on this recommendation

By Scott Hensley, NPR News

Oct. 10, 2011

New Models Predict Likelihood of Erectile Function Return After Prostate Cancer Treatment

Problem still there but it helps men make better informed decisions with realistic expectations - watch video report

Sept. 20, 2011

New Surgery-Free Treatment for Enlarged Prostate Avoids Sexual Dysfunction

Prostatic artery embolization as effective as popular TURP surgical method; more than half of senior men have enlarged prostate; also silodosin a new treatment for prostatitis

May 18, 2011


Ten Ways to Improve Communications, Make Better Decisions About Your Cancer Care

Michigan researchers outline how to improve communication about the risk

Sept. 20, 2011

Concern Is Growing That the Elderly Get Too Many Medical Tests; Little Benefit

Growing skepticism about widespread, routine screening for cancer and other ailments of people in their 70s, 80s and 90s

By Sandra G. Boodman, Kaiser Health News

Sept. 13, 2011

Prostate Cancer Patients Live Much Longer with Hormone Therapy Added to Radiation

Larger graphs of prostate cancer cases and deaths 1987-2007 below story

ADT therapy works well with intermediate grade cancer, not so well with low grade; only two grades tested in this trial

July 15, 2011

Medicare Bites Bullet to Cover Expensive Provenge, Prostate Cancer Drug for Bad Cases

CMS also to continue expensive breast cancer drug, Avastin; Sipuleucel-T activates immune system to defend against prostate cancer; first approved autologus cellular immunotherapy

July 1, 2011

Cancer Death Rates Continue Decline That Began in Early 1930s Says Cancer Society

Cancer Statistics 2011 shows among men the reduction in lung, prostate, and colorectal cancers is nearly 80% of decline; among women, almost 60% of decrease in breast and colorectal - see chances of seniors getting cancer

June 17, 2011

Drug Approved to Treat Nail Fungus Found to Delay Chemo in Advanced Prostate Cancer

Itraconzole slows prostate cancer progression but has potential of serious side effects

June 3, 2011

Rising PSA Levels May Sometimes Lead to Negative Biopsies But Usually Means Cancer

News study shows nearly 70 percent with rising PSA eventually get prostate cancer

May 18, 2011


 
 

Read the latest news
> Health & Medicine
>
Today's Headlines

 

Some think these tumors should be rebranded as something else, such as idle tumors, to reflect the fact that they're not all that threatening and don't necessarily need to be treated. The analogy, though imperfect, is that some early skin cancers are called "actinic keratoses" and early cervical cancers are termed "dysplasias."

This week's sessions made clear there isn't much evidence to show whether deferring surgery and radiation for low-risk prostate cancer gives a man as good a shot at surviving the disease as immediate treatment.

This story comes from our partner 's Shots blog

But surprisingly, the panel says there's no need to do a big study that randomly assigns men with newly diagnosed low-risk tumors to observation or treatment, if their life expectancy is less than 20 years. Such a study would have to be very big and very long to pick up a mortality difference.

For men expected to live longer than two decades, the panel does call for a randomized study. It will be interesting to see whether more men volunteer for such a study than were willing back in 1994, when the only such US study on this issue had a lot of trouble persuading men to be randomized.

That study, called PIVOT, figured heavily in the panel's deliberations. The results were presented at an American Urological Association meeting in May. The results haven't been published in a peer-reviewed journal yet.

More about PIVOT in a sec, but first some perspective.

The great majority of the 240,000 US men diagnosed with prostate cancer each year have low-risk disease, as defined by a Gleason score of 6 or less. (Gleason scores combine how many cancerous cells are seen in a needle-biopsy tissue sample, and how aggressive the cells appear to be.)

More than half of all prostate cancers get a Gleason score of 6, the lowest score usually given. In fact, the panel notes that as many as 70 percent of prostate cancers these days are Gleason 6s, and thus low-grade. Why is that? Widespread PSA testing is catching very early cancers.

Think about that for a minute: The great majority of prostate cancers are low-risk. These cancers aren't likely to kill them. And yet only 1 in 10 men diagnosed with prostate cancer defers immediate treatment that aims to cure the condition in favor of observation.

Observation takes two different forms. There's "active surveillance," which aims to pick up signs that a low-risk tumor is becoming more aggressive. That means regular PSA tests, digital rectal exams and periodic needle biopsies. The hope is that a progressing cancer can be identified in time to cure it. The other approach is "watchful waiting." Doctors wait for symptoms to appear, which indicates the cancer has advanced.

The panel says these observational strategies are "under-utilized...for reasons that are not fully understood." It strongly implies that many doctors, and especially urologic surgeons, present observational approaches "in a negative way...as 'doing nothing.' "

But by choosing immediate treatment, men with low-risk prostate tumors are subjecting themselves — perhaps unnecessarily — to high rates of urinary and bowel incontinence and impotence, and many of these side effects don't go away.

Of patients who do choose to defer treatment, a quarter will change their minds within two to three years, and perhaps a half by five years. "The reasons for leaving active surveillance are often unclear," the panel says.

The best evidence for considering active surveillance or watchful waiting is that the PIVOT trial, which compared 731 men with prostate cancer randomly assigned to surgical removal of their prostate or observation.

After an average of 10 years of followup, about half the patients had died. But only 7 percent died of prostate cancer (as far as the researchers could determine), and the risk of dying (from prostate cancer or any cause) was not significantly different between the "treatment" and "observation" groups – if the tumor was initially deemed low-risk.

An earlier Scandinavian study did find that men who underwent immediate treatment had lower risk of dying than those who underwent watchful waiting. But that was back in the days when prostate cancer was typically more advanced at the time of diagnosis, and observation of untreated patients may have been less likely to pick up progressing cancers.

It remains to be seen, of course, how much influence the NIH panel's statement will have on the real-world practice of prostate cancer treatment, and the choices of patients.

The panel heard from one man, Catholic University law professor David Lipton, who said he deliberately rejected active surveillance three years ago, even though he had a low-risk tumor. And he'd do it again.

"Ultimately...the decision was very visceral and personal," Lipton says. "I did not want to wake up each morning wondering if the previous night was the night that a cancer cell 'flew' from my prostate and invaded other reaches of my body."

The fact that he no longer has a prostate that might seed a fatal metastasis "gives me some comfort, even though a number of studies suggest it should not," Lipton says.

His decision might be different, Lipton says, if scientists develop reliable tests that predict if a prostate tumor really is indolent or aggressive, and if future data indicates that men who get treated after a period of observation do as well as those who get treated up-front.

As with any expert panel, this one did recommend, urgently, a number of studies, in addition to the big trial comparing treatment and observation among younger men with low-risk tumors. Much remains to be done, it said, to define just what observation means, to make sure men labeled low-risk really are, to come up with better ways to tell if a low-risk tumor has progressed, and so on.

Some of this information is reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

>> http://www.npr.org/

 

> Medical Malpractice,

> Nursing Home Abuse,

> Personal Injury

Our Experienced Lawyers Can Help

Beth Janicek, Board Certified Personal Injury Attorney"We win because we care, we prepare and we have no fear," Beth Janicek, board certified personal injury attorney

 

Free Consultation on your case.

Call Now Toll Free

1-877-795-3425

or Send Email

More at our Website

 

 

Search for more about this topic on SeniorJournal.com

Google Web SeniorJournal.com

Keep up with the latest news for senior citizens, baby boomers

 

Click to More Senior News on the Front Page

Copyright: SeniorJournal.com

    

 

Published by New Tech Media - www.NewTechMedia.com

Other New Tech Media sites include CaroleSutherland.com, BethJanicek.com, SASeniors.com, DrugDanger.com, etc.